Trial Profile
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Indicators of Clinical Response in Immunomodulatory Treatment-naïve Unresectable Stage III/IV Melanoma Patients Receiving REGN2810 (Anti-PD-1)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Apr 2020
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 16 Apr 2020 Status changed from active, no longer recruiting to completed.
- 14 Nov 2019 Planned End Date changed from 22 Oct 2019 to 30 Mar 2020.
- 18 Jun 2019 Planned End Date changed from 21 Oct 2019 to 22 Oct 2019.